Skip to main content

Table 2 Responses details, stratification by BM response

From: Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

Characteristics All patients, n = 58 BM-NR, n = 29 BM-PR, n = 16 BM-CR, n = 13
Initial HR, no. (%) 54 (93) 26 (90) 15 (94) 13 (100)
Last HR, no (% of initial HR) 22 (41) 7 (27) 5 (33) 9 (69)
Duration of HR, months (range) 90 (10–101) 50 (10–98) 69 (17–96) 87 (59–101)*
Initial MR, no. (% of JAK2+), type 33/44 (75)
9 CMR, 20 PMR, 4 mMR
15 (68)
2 CMR, 11 PMR, 2 mMR
8 (89)
6 PMR, 2 mMR
10 (91)
7 CMR*, 3 PMR
Last MR, no (% of initial overall MR), type 22 (67)
9 CMR; 4 PMR, 9 mMR
7 (47)a
2 CMR, 5 mMR
6 (75)
3 PMR, 3 mMR
9 (90)
7 CMR, 1 PMR, 1 mMR
Time to BM response, months (range) 52 (12–72) NA 54 (12–72) 52 (30–72)b
BM response duration, months (range) 36 (12–66) NA 36 (12–66) 30 (24–52)
Last BM response, no (% of initial), type 9 BM-CR; 14 BM-PR NA 14 BM-PR (88)
2 BM-NR (12)
9 BM-CR (69)
4 BM-NR (31)
Vascular adverse event on therapy, No (%) 6 (10) 3 (10) 2 (13) 1 (8)
MF transformation on therapy, no (%) 4 (7) 4 (14) 0 0
Duration of therapy, months (range) 80 (15–107) 75 (25–205) 85 (77–107) 83 (15–101)
Total median follow-up, months (range) 84 (36–107) 81 (36–105) 94 (67–107) 93 (83–106)
On study at last follow-up, no (%) 32 (55) 10 (35) 13 (81) 9 (69)*
  1. DX diagnosis, HR hematologic response, MR molecular response
  2. * p < 0.05
  3. aOne patient was not evaluable for subsequent MR
  4. b8/13 patients with BM-CR (61%) achieved complete resolution of reticulin fibrosis (MF-0) after a median of 63 months on therapy (range 30–72); the remaining 5 patients has decreased their BM fibrosis to MF 0/1 after a median of 48 months (range 30–69) on therapy